Hormones and the Gut-Microbiome Connection During Menopause: How Bacteria Shape Hormonal Balance

Menopause is not only an ovarian transition but a systemic event that reshapes endocrine, immune, and gastrointestinal physiology. Emerging evidence highlights the role of the gut microbiome — particularly the estrobolome subset of bacteria that modulate estrogen metabolism — in determining circulating hormone levels and symptom burden. This article summarizes physiological mechanisms, key microbial players, and evidence-based strategies for supporting gut-hormone balance. For a focused overview, see Hormones and the Gut‑Microbiome Connection During Menopause.

During perimenopause and menopause, ovarian production of estrogen and progesterone declines while gonadotropins (FSH, LH) rise. Estrogen supports tight junction proteins in the intestinal epithelium, modulates mucosal immunity, and influences gut motility via enterochromaffin cells and serotonin pathways. Loss of estrogen can therefore increase intestinal permeability, shift immune tone toward pro-inflammatory states, and alter motility patterns — all of which affect microbial composition and function.

A key mechanism linking bacteria to systemic hormones is the enterohepatic circulation of estrogens. The liver conjugates estrogens (glucuronidation/sulfation) and excretes them into bile. In the gut, bacteria expressing β-glucuronidase or sulfatase can deconjugate these compounds, freeing estrogens for reabsorption. The collective bacterial genes and taxa that perform these reactions are often called the estrobolome; their activity influences how much active estrogen returns to circulation.

Certain taxa are repeatedly implicated in estrogen metabolism and gut barrier function:

• Escherichia coli and some Clostridia: common sources of β-glucuronidase activity.
• Bacteroides spp.: involved in deconjugation and bile acid interactions.
• Faecalibacterium prausnitzii, Lactobacillus, Bifidobacterium: associated with anti-inflammatory effects and epithelial integrity.
• Ruminococcus spp.: fiber fermentation and short-chain fatty acid (SCFA) production that support mucosal health.

Balanced β-glucuronidase activity is important: excessive deconjugation may prolong estrogen exposure, while insufficient activity could reduce circulating estrogen availability.

Recent observational and interventional studies report lower microbial alpha diversity in many postmenopausal cohorts, shifts in SCFA-producing taxa, and correlations between β-glucuronidase activity and estrogen metabolites. Trials using prebiotic fiber, selected probiotics, and dietary modulation have demonstrated modest effects on inflammatory markers, microbiome composition, and metabolites relevant to hormone metabolism.

• Diet: increase dietary fiber and a variety of fermentable substrates (legumes, whole grains, vegetables) to support SCFA producers.
• Prebiotics and fermented foods: may promote beneficial taxa linked to barrier integrity.
• Probiotics: target-specific strains can influence inflammation and microbial functions; evidence is strain-specific and mixed.
• Clinical options: hormone replacement therapy and microbiome-directed therapies are medical decisions requiring clinician input.

For further reading on individualized probiotic needs and the broader microbiome landscape, consult How Your Unique Microbiome Dictates Your Probiotic Needs and Gut Microbiome: The Good, The Bad, and The Ugly. A related resource on testing options can be found at microbiome test.

Menopause-induced hormonal changes and the gut microbiome interact bidirectionally via mechanisms such as the estrobolome and immune modulation. Supporting gut microbial diversity and mucosal health through diet and lifestyle can be a complementary approach to managing menopausal physiology, while clinical therapies remain individualized and evidence-guided.